Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Bial bails after Parkinson’s fail, axing asset over phase 2 miss
Bial has stopped development in a subpopulation of Parkinson’s disease patients after its phase 2b trial missed its primary endpoint.
Nick Paul Taylor
Jun 9, 2026 5:22am
Novartis ‘always looking’ for new ways to shuttle drugs to brain
May 28, 2026 8:44am
Biogen axes Denali-partnered Parkinson’s drug after phase 2 flop
May 22, 2026 6:12am
Herantis taps Indivi for digital biomarker tech in new trial
May 19, 2026 7:45am
Novo salvages happy ending for scrapped Parkinson’s therapy
May 11, 2026 8:30am
Oryon shines out of stealth with $21M to fight Parkinson's
Mar 23, 2026 5:00am
